Nitric oxide-producing myeloid-derived suppressor cells inhibit vascular E-selectin expression in human squamous cell carcinomas

Ahmed Gehad1,2, Michael Lichtman1,2, Chrysalyne Schmults1, Jessica E. Teague1, Adam Calarese3, Ying Jiang4, Rei Watanabe1, and Rachael A. Clark1

1Harvard Skin Disease Research Center and the Department of Dermatology, Brigham and Women’s Hospital, Boston, MA 02115
3Drexel University College of Medicine, Philadelphia, PA
4Temple University School of Medicine, Philadelphia, PA

Abstract

Squamous cell carcinomas (SCC) are sun-induced skin cancers that are particularly numerous and aggressive in immunosuppressed individuals. SCC evade immune detection at least in part by down-regulating E-selectin on tumor vessels, thereby restricting entry of skin homing T cells into tumors. We find that nitric oxide potently suppresses E-selectin expression on human endothelial cells and that SCC are infiltrated by nitric oxide-producing iNOS+ CD11b+ CD33+ CD11c− HLA-DR− myeloid-derived suppressor cells (MDSC). MDSC from SCC produced NO, TGFβ and arginase and inhibited endothelial E-selectin expression in vitro. MDSC from SCC expressed the chemokine receptor CCR2 and tumors expressed the CCR2 ligand HBD3, suggesting CCR2-HBD3 interactions may contribute to MDSC recruitment to SCC. Treatment of SCC in vitro with the iNOS inhibitor L-NNA induced E-selectin expression at levels comparable to imiquimod-treated SCC undergoing immunologic destruction. Our results suggest that local production of NO in SCC may impair vascular E-selectin expression. We show that MDSC are critical producers of NO in SCC and that NO inhibition restores vascular E-selectin expression, potentially enhancing T cell recruitment. iNOS inhibitors and other therapies that reduce NO production may therefore be effective in the treatment of SCC and their premalignant precursor lesions actinic keratoses.

Introduction

Over 700,000 SCC are diagnosed each year in the United States (Rogers et al.). The treatment of non-melanoma skin cancers, of which SCC is the second most frequent type, account for 4.5% of all Medicare cancer costs (Berg and Otley, 2002; Housman et al., 2003).
Although most are curable by surgical excision, 4% metastasize to the lymph nodes and 1.5% of SCC patients die from metastatic or locally aggressive disease (Brantsch et al., 2008). SCC are a leading cause of death among organ transplant recipients. These patients have a 65- to 250-fold increased risk of developing SCC; nearly 10% of these cancers metastasize and the majority of patients die as a result (Berg and Otley, 2002; Euvrard et al., 2003). Currently, wide surgical excision is the only treatment for invasive SCC. In addition to the burden of invasive cancers, actinic keratoses, the premalignant precursor lesion of SCC, are the third most frequent reason in the U.S. for consulting a dermatologist (Feldman et al., 1998). Over 5.2 million physician visits are made each year for the treatment of actinic keratoses at a cost of over $900 million (Warino et al., 2006).

Immune evasion in human SCC appears to primarily result from aberrant T cell homing. Vessels in SCC lack expression of E-selectin, a skin addressin that is expressed at baseline by cutaneous postcapillary venules, is up-regulated with inflammation, and by binding to cutaneous lymphocyte antigen (CLA) on skin homing T cells, mediates the first step of T cell recruitment into skin (Chong et al., 2004; Clark et al., 2008; Kupper and Fuhlbrigge, 2004). As a result, these tumors exclude CLA+ skin homing T cells, the cell type that provides cutaneous immune surveillance and would be expected to contain tumor specific T cells (Clark, 2010).

Topical treatment of SCC with the TLR7 agonist imiquimod induces endothelial activation, massive infiltration of tumors by CLA+ T cells producing IFNγ, perforin, and granzyme, tumor cell death and histologic evidence of tumor regression (Clark et al., 2008; Huang et al., 2009). This rapid and effective immune response suggests that primed SCC-specific T cells exist in the circulation but these cells cannot gain access to the tumor. Imiquimod can be used to treat SCC in poor surgical candidates (Peris et al., 2006). In solid organ transplant recipients, a course of imiquimod was effective and did not engender graft rejection in the 6 or 12 months that patients were followed (Brown et al., 2005; Ulrich et al., 2007) but concerns linger that repeated use of imiquimod could engender graft rejection or shorten the life of an allograft. There is therefore a need to understand why blood vessels in SCC fail to express T cell homing addressins such as E-selectin and to identify novel agents that can induce endothelial activation and restore appropriate T cell homing without broad, nonspecific activation of the immune system. Below, we present our findings that nitric oxide (NO) production in SCC contributes to suppression of E-selectin expression by tumor vessels and that agents that inhibit NO production may be effective therapeutic strategies for the treatment of SCC.

**Results**

**Vascular E-selectin expression correlates with tumor infiltration by CLA+ T cells and histologic evidence of tumor regression**

We previously observed qualitative increases in vascular E-selectin expression and T cell infiltration after TLR7 agonist treatment of SCC (Clark et al., 2008; Huang et al., 2009). To quantitatively study the relationship of vascular E-selectin expression and tumor infiltration by skin homing CLA+ T cells, we counted the percentage of tumor vessels expressing E-selectin and the number of infiltrating CLA+ T cells in untreated SCC and SCC treated with
TLR7 agonist prior to excision. In agreement with earlier observations, vascular E-selectin expression was absent or low in untreated tumors and markedly up-regulated in SCC treated with the TLR7 agonist imiquimod (Fig. 1, a and d). In untreated tumors, 6.7% of blood vessels in tumors expressed E-selectin (n=5, SEM 1.53) whereas 34.2% of blood vessels expressed E-selectin in tumors treated with TLR7 agonist prior to excision (n=3, SEM 3.04). The difference between treated and untreated SCC was statistically significant (p<0.0001). Likewise, recruitment of CLA+ T cells was low in untreated SCC but greatly enhanced in treated tumors (Fig. 1, b, c, and d). Untreated tumors were infiltrated by a mean 21.3 CLA+ T cells per high power field (HPF, n=6, SEM 5.91) whereas tumors treated with TLR7 agonist prior to excision contained a mean 256.6 CLA+ T cells per HPF (n=3, SEM 5.91, p=0.0002). There was in fact a strong linear correlation between vascular E-selectin expression and infiltration by CLA+ T cells (correlation coefficient R=0.94) and only tumors with both features had histologic evidence of tumor regression (Fig. 1d).

**SCC are infiltrated by NO producing CD11c−CD11b+HLA-DR− myeloid-derived suppressor cells**

Cells expressing iNOS were prominent in untreated SCC (Fig. 2, a and b)(Clark et al., 2008). We previously observed faint staining of iNOS+ cells for CD11c, suggesting a possible dendritic cell lineage. However, follow up staining with multiple anti-CD11c antibodies demonstrated that these cells were in fact CD11c−, CD11b+, and HLA-DR−, a phenotype shared by myeloid derived suppressor cells identified in several human cancers (MDSCs) (Fig. 2c,d,h) (Corzo et al., 2010; Diaz-Montero et al., 2009; Filipazzi et al., 2007; Gabitass et al., 2011). iNOS+ cells lacked expression of the macrophage marker CD163, the T cell marker CD3 and the endothelial cell marker CD34 (Fig. 2e-g) and were CD14− (data not shown). Further characterization by flow cytometry analysis of dispersed cells isolated from collagenase-treated SCC demonstrated that CD11b+ HLA-DR− cells expressed CD33, a subset expressed iNOS and the majority expressed TGFβ, a phenotype consistent with human MDSC (Fig. 3a). RT-PCR analysis of CD11b+ cells isolated by magnetic bead separation from collagenase dispersed tumors demonstrated that CD11b+ cells expressed arginase I (Fig 3b). iNOS+ CD11b+CD11c−HLA-DR− cells were present in 16/16 untreated SCC (10 SCC were studied by immunostaining of cryosections and 6 by flow cytometry analysis of collagenase treated tumors). As we previously reported, iNOS+ cells were not present in imiquimod treated SCC undergoing regression (Clark et al., 2008). CD11b+ HLA-DR− cells made up a mean 6% of total tumor cells in collagenase digested SCC but were rare (0.8%) in normal human skin (Fig. 3c). Selective gating on iNOS-expressing cells demonstrated that MDSC were the prominent cell type expressing iNOS in most tumors, although it was also expressed by other cell types within the tumor microenvironment (Fig. 3d). A mean 51% of total iNOS+ cells in four collagenase digested SCC were CD11b+ CD11c− HLA-DR− CD33+ MDSC (SEM 10.3).

To confirm that NO was produced within the SCC tumor microenvironment, we measured nitrate and nitrite levels from tumor supernatants using the Griess method (Fig. 3e). Although levels varied, significant NO production was observed in all tumors analyzed (significance of difference medium vs. SCC supernatants, p<0.05). To confirm that MDSC in SCC produced NO, we isolated CD11b+ cells using magnetic bead separation of...
collagenase dispersed tumors. CD11b enrichment produced a fairly uniform population of CD11b$^+$ HLA-DR$^{low}$ cells (Fig. 3f) and analysis of the culture supernatants of these cells demonstrated that they produced NO (Fig. 3g).

**NO inhibits E-selectin expression by human dermal microvascular endothelial cells IN VITRO**

NO inhibits the expression of endothelial adhesion receptors on human umbilical vein endothelial cells (HUVEC) and reduces adhesion of dendritic cells to endothelial monolayers in vitro (De Caterina et al., 1995; De Palma et al., 2006). Gene expression analyses have found significant differences between HUVEC and the microvascular endothelial cells found in tissues such as the skin (Chi et al., 2003). We studied the effects of NO on human dermal microvascular endothelial cells (DMEC). To mimic the physiologic stimulation likely to occur within the tumor microenvironment, DMEC were co-cultured with TLR7 agonist-stimulated T-cell depleted peripheral blood mononuclear cells (APC). Under these conditions, NO potently inhibited endothelial E-selectin expression (Fig. 4a and b). However, NO only partially inhibited E-selectin expression when endothelial cells were stimulated with 10 ng/ml of TNFβ. A similar biology was observed in umbilical vein endothelial cells (HUVEC); NO completely inhibited E-selectin expression after physiologic stimulation with APC but only partially inhibited expression after intense endothelial stimulation with TNFβ (Fig. 4b).

**MDSC from SCC suppress endothelial E-selectin expression in vitro**

To determine if cell types in SCC are capable of suppressing endothelial E-selectin expression, we cultured human HUVEC in the presence of unfractionated cells from collagenase dispersed SCC tumors. We observed a modest suppression of E-selectin under these conditions (Fig. 4c). We then separated collagenase dispersed SCC into CD11b$^+$ and CD11b$^-$ fractions using magnetic bead separation (Fig. 3f) and tested the ability of these cells to suppress endothelial E-selectin expression (Fig. 4d and e). CD11b$^+$ cell fractions reproducibly inhibited endothelial E-selectin expression whereas CD11b$^-$ fractions had no effect or modestly increased E-selectin expression.

**MDSC from SCC express CCR2 and SCC produce the CCR2 ligand HBD3**

MDSC from both mice and humans express the chemokine receptor CCR2 and CCL2 production by human tumors has been implicated in the migration of MDSC into tumors (Huang et al., 2007). MDSC from collagenase dispersed SCC expressed CCR2 by flow cytometry analysis whereas T cells from the same tumors did not (Fig. 5a). Co-immunostaining for iNOS and CCR2 in tumor cryosections confirmed that iNOS$^+$ cells expressed CCR2 (Fig. 5b). Quantitative RT-PCR analysis of SCC tumors showed that the CCL2 ligands CCL2, CCL7, CCL13 and HBD2 were expressed at comparable levels in normal skin and SCC, whereas only the CCL2 ligand HBD3 was expressed at significantly higher levels in SCC (Fig. 5c). Immunostaining of SCC cryosections confirmed production of HBD3 in SCC tumors (Fig. 5d).
iNOS inhibition induces SCC vascular E-selectin expression IN VITRO

To determine if NO production in tumors locally inhibits vascular E-selectin expression, we cultured portions of human SCC for 24 hours in the iNOS inhibitor L-NNA in the presence or absence of TNFβ and then assayed for E-selectin expression by immunostaining of cryosections. We observed a marked up-regulation of E-selectin expression in tumors treated with iNOS inhibitor (Fig. 6, a and b). E-selectin was expressed on a mean 1.9% of blood vessels in SCC treated with control medium (n=4 tumors, SEM 0.58). After treatment with iNOS inhibitor, E-selectin was expressed by a mean 27.1% of tumor vessels (n=4, SEM 1.06, control medium vs. iNOS inhibitor p<0.0001). As expected, treatment of SCC with TNFβ also increased expression of E-selectin (mean 19.6% positive vessels, SEM 2.17, n=4, control medium vs. TNFβ treated p= 0.0002). Combining iNOS inhibition and treatment with TNFβ provided no additional increase in E-selectin expression above the use of iNOS inhibitors alone (iNOS inhibitor vs. TNFβ/iNOS inhibitor p=0.45).

Discussion

Impairment of T cell homing is a major mechanism by which cutaneous SCC evade immune responses. Vessels in SCC tumors lack expression of E-selectin and exclude the population of CLA+ T cells thought to provide immune surveillance in the skin (Clark et al., 2008). Induction of E-selectin expression on blood vessels by TLR7 agonist therapy leads to infiltration of the tumors by CLA+ T cells producing IFNγ, perforin and granzyme, and is associated with histologic evidence of tumor regression (Clark et al., 2008; Huang et al., 2009). These clinical responses suggest that tumor specific T cells exist within the circulation but cannot gain access to the tumor. Thus, the induction of appropriate T cell homing addressins on tumor vessels has the potential to restore homing and potentially induce tumor destruction.

We report here that human SCC are infiltrated by a population of NO producing cells that express CD11b, CD33 and lack CD11c and HLA-DR, a phenotype suggestive of MDSC (Diaz-Montero et al., 2009; Gabrilovich and Nagaraj, 2009). MDSC are a heterogenous population of myeloid cells that are enriched in the circulation of cancer patients as well as in many animal tumor models. MDSC play a major role in cancer related immunosuppression and can potently suppress T cell responses (Nagaraj et al., 2010). The majority of CD11b+CD11c−HLA-DR− cells isolated from SCC expressed i-NOS, TGFβ, and arginase I, three critical effector mechanisms used by MDSC to suppress T cell responses (Gabrilovich, 2004; Jia et al., 2010; Li et al., 2009). CD11b+HLA-DR− cells comprised approximately 6% of total cells in SCC, but were rare in normal skin (Fig. 3c).

iNOS, a key enzyme that catalyzes NO production, is expressed in a variety of human cancers including malignant melanoma, breast, lung, prostate, and colorectal cancers (Lechner et al., 2005). iNOS expression correlated with progression in human astrocytoma and prostate cancer, and patients with iNOS+ melanomas had decreased survival (Ekmekcioglu et al., 2006; Lechner et al., 2005; Tanese et al., 2011). NO has a variety of effects on immune cells including inhibition of T cell activation, proliferation, and cytokine production (Bogdan, 2001) and animal studies suggest it may also reduce the adhesion of leukocytes to blood vessels. Inhibition of NO increased leukocyte rolling and adhesion in
mesenteric venules in cats and rats and P-selectin expression was increased in rats after perfusion with NO inhibitors (Davenpeck et al., 1994; Kubes et al., 1991). In a mouse cancer model in which mouse mammary adenocarcinoma and human colon carcinoma cell lines were injected into the skin, treatment of animals with the iNOS inhibitor L-NAME led to increased rolling and stable adhesion of leukocytes to tumor vessels (Fukumura et al., 1997).

We find that NO is produced by SCC tumors and that CD11b+ MDSC expressed iNOS and are significant sources of NO production within the SCC microenvironment. Small numbers of CD11b+ HLA-DR“low” cells isolated from SCC potently suppressed endothelial E-selectin expression, suggesting that even though MDSC comprise a relatively small percentage of total tumor cells, they may play a critical role in down regulating vascular E-selectin and impairing T-cell trafficking into tumors. In a mouse model of B16 melanoma, MDSC inhibited the migration of activated CD8 T cells into tumors but the mechanism of impaired T-cell homing was not identified (Lesokhin et al., 2011). Our results suggest that NO produced by MDSC inhibits vascular E-selectin, likely impairing T cell migration in to tumors, and that this may be another mechanism by which MDSC impair anti-tumor immunity.

Human studies have been limited but in vitro treatment of HUVEC with NO has been shown to reduced addressin expression and dendritic cell adhesion (De Caterina et al., 1995; De Palma et al., 2006). We found that NO completely abrogated the expression of E-selectin when DMEC were physiologically stimulated with activated APC, but could only partially inhibit E-selectin expression when endothelial cells were strongly and directly stimulated with 10 ng/ml of TNFβ (Fig. 4a, b). It may therefore be possible to overcome impaired E-selectin expression by either inhibiting iNOS activity or by potently and directly stimulating endothelial cells. We found that HUVEC and DMEC derived from human skin responded very similarly to NO, suggesting that HUVEC, which are easier to obtain and grow, may be useful in drug screens used to identify novel agents that activate endothelial cells.

MDSC in both humans and animal models express the chemokine receptor CCR2 (Huang et al., 2007; Lesokhin et al., 2011). CCL2 is produced by human breast, gastric and ovarian cancers and inhibition of CCR2-CCL2 signaling in mouse cancer models reduced MDSC migration and MDSC-induced tumor cell growth (Huang et al., 2007). In addition to their antimicrobial function, HBD-2 and HBD-3 can induce cell chemotaxis via CCR2 (Rohrl et al., 2010). HBD3/CCR2 interactions promoted migration of macrophages into tumors in a mouse model of oral carcinoma (Jin et al., 2010). We found that iNOS+ MDSC in SCC tumors expressed CCR2 and SCC tumors expressed the CCR2 ligand HBD3, suggesting that CCR2-HBD3 interactions may play a role in the recruitment of MDSC to tumors (Fig. 5).

Lastly, we tested the ability of iNOS inhibitors and TNFβ to restore E-selectin expression in freshly excised human SCC tumors. iNOS inhibition alone markedly enhanced E-selectin expression on tumor vessels (Fig. 6). Remarkably, iNOS inhibition alone induced E-selectin expression at similar or greater levels than TNFβ. Moreover, E-selectin was expressed at levels comparable to those observed in SCC undergoing immunologic destruction after topical treatment with TLR7 agonist (Fig. 1d and 6b). SCC undergoing immunologic
destruction after TLR7 agonist therapy expressed E-selectin on a mean 34.2% of blood vessels as compared to 27.2% of blood vessels following in vitro treatment with iNOS inhibitor (p>0.05). Although the limitations of working with humans preclude us from directly demonstrating that T cell recruitment into SCC is enhanced as a result of iNOS inhibition, these studies strongly suggest that iNOS inhibition induces vascular E-selectin at levels capable of enhancing T cell entry into tumors. To our knowledge, it is previously unreported in a human cancer that iNOS activity impairs the expression of vascular addressins critical for T cell recruitment.

Our results suggest that treatment with iNOS inhibitors or potent stimulators of endothelial activation both have the potential to restore addressin expression in SCC without the attendant widespread immune activation observed with TLR agonists such as imiquimod. A topicaly applied inhibitor of iNOS is currently in clinical trials for the treatment of neuropathic pain (LaBuda et al., 2006). Because immune evasion in SCC is primarily an issue of impaired T cell homing, our studies suggest that topically applied iNOS inhibitors or potent endothelial activating agents may be effective, either alone or in combination with other therapies, in the treatment of SCC and their premalignant precursor lesions, actinic keratoses.

It is becoming increasingly appreciated that cancer destruction requires not only the generation of tumor specific T cells but also the ability of these T cells to access the tumor once they are generated (Gajewski, 2007). Impaired T cell homing as a result of decreased vascular addressin expression has been reported in a number of human cancers, including malignant melanoma, breast, gastric and lung cancers (Madhavan et al., 2002; Piali et al., 1995; Weishaupt et al., 2007). Melanoma metastases express low levels of the addressins E-selectin, P-selectin and ICAM-1 and this is associated with low numbers of T cells within the metastatic tumor nodules (Weishaupt et al., 2007). Our work suggests that local production of NO within tumors could be a common mechanism for impaired T cell homing. If this proves to be the case, iNOS inhibition used in concert with agents that enhance the presentation of tumor antigens have the potential to enhance immune responses to many human cancers.

Materials and methods

SCC samples

Tumor samples consisted of tumor removed prior to taking the first Moh’s section during Moh’s micrographic excision of biopsy-proven squamous cell carcinomas removed from immunocompetent individuals. Acquisition of tumor samples and all studies were approved by the Partners Institutional Review Board and were performed in accordance with the Declaration of Helsinki. Because this work utilized discarded tissues with no identifiable personal information, the Partners IRB ruled that no informed written patient consent was required.
**Immunofluorescence studies**

Five μm sections were cut from SCC blocks frozen in OCT. Sections were fixed in acetone, air dried, rehydrated in PBS and blocked with human IgG (Jackson Immunoresearch). Sections were incubated with a biotinylated anti E-selectin (clone 68-5H11, BD) at 5 ug/ml, rinsed in PBS/1% BSA, and co-stained with streptavidin-PE (1 ug/ml, R&D Systems) and CD31 FITC (1:40 clone WM59, BD). Sections were rinsed and mounted with ProLong Gold antifade reagent with DAPI (Invitrogen). E-selectin+ blood vessels were enumerated in ten 100X high power fields (HPF). To quantify CLA+ T cells, sections were co-stained with PE anti-CD3 (1:40, BD) and FITC anti-CLA (1:25, BD). The number of CLA+ infiltrating T cells was determined by counting CLA+ cells directly in 10 HPF or by counting total T cells in 10 HPF and multiplying by the % CLA+ T cells of total T cells obtained from 5 HPF. For examination of iNOS-expressing cells, sections were co-stained with directly conjugated monoclonal antibodies (BD) and FITC anti-iNOS (1:20, BD). For HBD3 staining, sections were stained with rabbit anti human HBD-3 mAb (1:00, FL-67 Santa Cruz Biotech) followed by Alexa Fluor 488 goat anti rabbit polyclonal antibody (1:100, Invitrogen). In all studies, DAPI nuclear stain was used to confirm the presence of invasive tumor as determined by the presence of large atypical keratinocyte nuclei. Sections were photographed using a Nikon Eclipse 6600 microscope equipped with Nikon Plan Fluor objective lenses. Images were captured with a SPOT RT model 2.3.1 camera (Diagnostic Instruments) and were acquired with SPOT 4.0.9 software (Diagnostic Instruments).

**Isolation and flow cytometry analysis of T cells and MDSC from SCC tumors**

For isolation of MDSC from SCC, tumors were minced and dissociated with 0.2% type I collagenase (Invitrogen) and 30 Kunitz Units/ml of DNAse (Sigma) for two hours at 37° with vigorous shaking. CD11b+ cells were isolated from collagenase treated tumors by staining with anti-CD11b-PE mAb (R&D systems) and anti-PE micro-beads (Miltenyi Biotech) followed by AutoMACS separation (Miltenyi Biotech). For TGFβ staining, cells were stimulated overnight with 1ug/ml LPS from *E. coli* (Sigma) and 100 IU/ml IFNγ (R&D systems) to activate MDSC (Greifenberg et al., 2009). Flow cytometry analysis was performed using directly conjugated monoclonal antibodies from BD. Analysis of flow cytometry samples was performed on a Becton Dickinson FACSCanto instrument and data were analyzed using FACSDiva software (BD).

**Assay of SCC supernatants and CD11b+ cells for NO production**

For analysis of SCC supernatants, 3 mm³ tumor fragments were cultured for 24 hours in Iscoves medium supplemented with 10% human AB serum, fungizone, gentamycin, penicillin/streptomycin, L-glutamine and 0.6 mM L-arginine. Supernatants were concentrated using Microcon centrifugal filter devices (Millipore Corp). For analysis of NO production from SCC CD11b+ cells, CD11b+ cells were isolated from collagenase treated SCC by magnetic bead separation as described and 10,000 CD11b+ cells were incubated for 12 hours with 1ug/ml *E. coli* LPS and 100 IU/ml IFNγ. Supernatants were assayed for nitric oxide using the QuantiChrom Nitric Oxide assay kit or the Parameter Total NO/Nitrite/Nitrate Assay Kit (R&D Systems), as per the manufacturer’s instructions.
**Endothelial cell studies**

Human dermal microvascular and umbilical vein endothelial cells (Lonza) were cultured in EGM-2 bulletkit growth medium (Lonza). Endothelial cells at 90% confluency were stimulated for 12 hours with activated APC or 10 ng/ml TNF-α (R&D systems) with or without 0.5 mM nitric oxide donor spermine NONOate (Sigma-Aldrich). Human peripheral blood APC were isolated from products discarded following plasmapheresis of healthy donors by density centrifugation using histopaque-1077 (Sigma) and depletion of T cells using the Pan-T isolation kit and AutoMACS instrument (Miltenyi Biotech). APC (2.5 x 10^6) and 3 μM imiquimod (added to stimulate APC) were added to wells containing cultured endothelial cells for 12 hr. Endothelial cells were then stained with directly conjugated antibodies to CD31 and E-selectin (BD) and acquired on a BD FACSCanto flow cytometer. Data were analyzed using FACS Diva software (V6.1). For experiments involving co-cultures of endothelial cells with cells from SCC tumors, cells obtained from collagenase treated SCC were rested overnight at in complete Iscove’s medium in the presence of 10 ng/ml GM-CSF (R&D systems) to maintain myeloid cell viability (Ko et al., 2009). Cells from SCC were added to endothelial cells in a 1:1 ratio and stimulated with 1 ng/ml TNF-α (R&D systems). In a second group of experiments, 5,000 AutoMACS-enriched CD11b+ cells from collagenase treated SCC were added to wells containing 5,000 endothelial cells stimulated with TNFα 1 ng/ml; immunostaining of endothelial cells was performed 12 hours later as described.

**Quantitative real-time PCR for CCR2 ligands and arginase I**

Total RNA was isolated from cryosections of SCC and normal skin or from cells isolated from SCC tumors using the RNeasy Lipid Tissue kit (Qiagen), according to the manufacturer’s instructions. cDNA was generated using the QuantiTect reverse transcription kit (Qiagen) and quantitative real-time PCR was performed using the ABI StepONE plus instrument and the Fast SYBR green master mix (Applied Biosystems). Expression of each ligand transcript was determined relative to the reference gene transcript, GAPDH, and calculated as 2^(-ΔΔCt) (ΔΔCt = Ct, ligand - Ct, GAPDH). The primers used to detect the ligands and the reference transcripts were purchased from Origene Technologies and were as follows: hBD2 (F-GGCCTAGAAGTTCTCTGTCTCC; R-GAAGGCAGAGAAAGGATGAG), hBD3 (F-GGTGAAGCCTAGCAGCTATGAG; R-GCCGCCTCTGACTCTGCAATA), CCL2 (F-AAGATACACAGCAGCAAGTGTCC, R-TCTGGACCCACTTCTCCTTG), CCL7 (F-ACAGAAGGACCACCAGTAGCCA; R-GGTGCTTCATAAAGTGCTGGACC), CCL13 (F-GATCTCCTTGCAGAGGCTGAAG; R-TCTGGACCCACTTCTCCTTTGG), GAPDH (F-GAGTCAGCGGATTTGTCGT; R-CATGGGTGGAATCATATTGG). 

**IN VITRO treatment of SCC with iNOS inhibitor and TNFβ**

SCC were cultured for 24 hours in control medium (Iscoves, 10% human AB serum, fungizone, gentamicin, penicillin/streptomycin, L-glutamine, 0.6 mM L-arginine) in the presence or absence of 0.6 mM iNOS inhibitor Nω-Nitro-L-arginine, (L-NNA, Sigma) and/or 10 ng/ml TNFβ (R&D), then embedded in OCT, cryosectioned and stained for CD31 and E-selectin as described.
Acknowledgments

Grant support

Normal skin was kindly provided by Drs. Bohdan Pomahac, Simon Talbot and Elof Eriksson of BWH and by Dr. Thomas Cochran of the Boston Center. This research was supported by grants NIH/NIAMS R01 AR056720 (to RAC), NIH/NIAID K08 AI060890 (to RAC), a Damon Runyon Cancer Research Foundation Clinical Investigator Award (to RAC), and a Scleroderma Foundation New Investigator Award (to RAC), and a Special Fellow Award from the Leukemia & Lymphoma Society (to RW).

Abbreviations used

- CLA: cutaneous lymphocyte antigen
- SCC: squamous cell carcinoma
- NO: nitric oxide
- MDSC: myeloid-derived suppressor cell
- iNOS: inducible nitric oxide synthase
- HBD: human beta defensin

References

Berg D, Otley CC. Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management. Journal of the American Academy of Dermatology. 2002; 47:1–17. [PubMed: 12077575]

Bogdan C. Nitric oxide and the immune response. Nature immunology. 2001; 2:907–916. [PubMed: 11577346]

Brantsch KD, Meisner C, Schonfisch B, Trilling B, Wehner-Caroli J, Rocken M, et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol. 2008; 9:713–720. [PubMed: 18617440]

Brown VL, Atkins CL, Ghali L, Cerio R, Harwood CA, Proby CM. Safety and efficacy of 5% imiquimod cream for the treatment of skin dysplasia in high-risk renal transplant recipients: randomized, double-blind, placebo-controlled trial. Arch Dermatol. 2005; 141:985–993. [PubMed: 16103328]

Chi JT, Chang HY, Haraldsen G, Jahnsen FL, Troyanskaya OG, Chang DS, et al. Endothelial cell diversity revealed by global expression profiling. Proc Natl Acad Sci U S A. 2003; 100:10623–10628. [PubMed: 12963823]

Chong BF, Murphy J-E, Kupper TS, Fuhlbrigge RC. E-Selectin, Thymus- and Activation-Regulated Chemokine/CCL17, and Intercellular Adhesion Molecule-1 Are Constitutively Coexpressed in Dermal Microvessels: A Foundation for a Cutaneous Immunosurveillance System. J Immunol. 2004; 172:1575–1581. [PubMed: 14734737]

Clark RA. Skin resident T cells: the ups and downs of on site immunity. The Journal of investigative dermatology. 2010; 130:362–370. [PubMed: 19675575]

Clark RA, Huang SJ, Murphy GF, Mollet IG, Hijnen D, Muthukuru M, et al. Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. The Journal of experimental medicine. 2008; 205:2221–2234. [PubMed: 18794336]

Corzo CA, Condamine T, Lu L, Cotter MJ, Youn JI, Cheng P, et al. HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. The Journal of experimental medicine. 2010; 207:2439–2453. [PubMed: 20876310]
Davenpeck KL, Gauthier TW, Lefer AM. Inhibition of endothelial-derived nitric oxide promotes P-selectin expression and actions in the rat microcirculation. Gastroenterology. 1994; 107:1050–1058. [PubMed: 7523213]

De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA Jr, et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest. 1995; 96:60–68. [PubMed: 7542286]

De Palma C, Meacci E, Perrotta C, Bruni P, Clementi E. Endothelial nitric oxide synthase activation by tumor necrosis factor alpha through neutral sphingomyelinase 2, sphingosine kinase 1, and sphingosine 1 phosphate receptors: a novel pathway relevant to the pathophysiology of endothelium. Arterioscler Thromb Vase Biol. 2006; 26:99–105. [PubMed: 16269668]

Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009; 58:49–59. [PubMed: 18446337]

Ekmekcioglu S, Ellerhorst JA, Prieto VG, Johnson MM, Broemeling LD, Grimm EA. Tumor iNOS predicts poor survival for stage III melanoma patients. International journal of cancer. 2006; 119:861–866.

Euvrard S, Kanitakis J, Claudy A. Skin Cancers after Organ Transplantation. N Engl J Med. 2003; 348:1681–1691. [PubMed: 12711744]

Feldman SR, Fleischer AB Jr, McConnell RC. Most Common Dermatologic Problems Identified by Internists, 1990–1994. 1998:726–730.

Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol. 2007; 25:2546–2553. [PubMed: 17577033]

Fukumura D, Yuan F, Endo M, Jain RK. Role of nitric oxide in tumor microcirculation. Blood flow, vascular permeability, and leukocyte-endothelial interactions. Am J Pathol. 1997; 150:713–725. [PubMed: 903284]

Gabitassi RF, Annels NE, Stocken DD, Pandha HA, Middleton GW. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother. 2011; 60:1419–1430. [PubMed: 21644036]

Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nature reviews. 2004; 4:941–952.

Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nature reviews. 2009; 9:162–174.

Gajewski TF. Failure at the Effector Phase: Immune Barriers at the Level of the Melanoma Tumor Microenvironment. 2007:5256–5261.

Greifenberg V, Ribechiini E, Rossner S, Lutz MB. Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development. European journal of immunology. 2009; 39:2865–2876. [PubMed: 19637228]

Housman TS, Feldman SR, Williford PM, Fleischer AB Jr, Goldman ND, Acostamadiedo JM, et al. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol. 2003; 48:425–429. [PubMed: 12637924]

Huang B, Lei Z, Zhao J, Gong W, Liu J, Chen Z, et al. CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer letters. 2007; 252:86–92. [PubMed: 17257744]

Huang SJ, Hijnen D, Murphy GF, Kupper TS, Calarese AW, Mollet IG, et al. Imiquimod Enhances IFN-gamma Production and Effector Function of T Cells Infiltrating Human Squamous Cell Carcinomas of the Skin. The Journal of investigative dermatology. 2009

Jia W, Jackson-Cook C, Graf MR. Tumor-infiltrating, myeloid-derived suppressor cells inhibit T cell activity by nitric oxide production in an intracranial rat glioma + vaccination model. Journal of neuroimmunology. 2010; 223:20–30. [PubMed: 20452681]
Jin G, Kawsar HI, Hirsch SA, Zeng C, Jia X, Feng Z, et al. An antimicrobial peptide regulates tumor-associated macrophage trafficking via the chemokine receptor CCR2, a model for tumorigensis. PloS one. 2010; 5:e10993. [PubMed: 20544025]

Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res. 2009; 15:2148–2157. [PubMed: 19276286]

Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A. 1991; 88:4651–4655. [PubMed: 1675786]

Kupper TS, Fuhlbrigge RC. Immune surveillance in the skin: mechanisms and clinical consequences. Nature reviews. 2004; 4:211–222.

LaBuda CJ, Koblish M, Tuthill P, Dolle RE, Little PJ. Antinociceptive activity of the selective iNOS inhibitor AR-C102222 in rodent models of inflammatory, neuropathic and post-operative pain. European Journal of Pain. 2006; 10:505–512. [PubMed: 16125426]

Lechner M, Lirk P, Rieder J. Inducible nitric oxide synthase (iNOS) in tumor biology: the two sides of the same coin. Semin Cancer Biol. 2005; 15:277–289. [PubMed: 15914026]

Lesokhin A, Hohl TM, Kitano S, Cortez C, Hirschhorn-Cymerman D, Avogadri F, et al. Monocytic CCR2+ Myeloid Derived Suppressor Cells Promote Immune Escape By Limiting Activated CD8 T Cell Infiltration Into The Tumor Microenvironment. Cancer research. 2011

Li H, Han Y, Guo Q, Zhang M, Cao X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol. 2009; 182:240–249. [PubMed: 19109155]

Madhavan M, Srivivas P, Abraham E, Ahmed I, Vijayalekshmi NR, Balaram P. Down regulation of endothelial adhesion molecules in node positive breast cancer: possible failure of host defence mechanism. Pathol Oncol Res. 2002; 8:125–128. [PubMed: 12172576]

Nagaraj S, Schrum AG, Cho HI, Celis E, Gabrilovich DI. Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol. 2010; 184:3106–3116. [PubMed: 20142361]

Peris K, Micantonio T, Furgnoli MC, Lozzi GP, Chimenti S. Imiquimod 5% cream in the treatment of Bowen's disease and invasive squamous cell carcinoma. J Am Acad Dermatol. 2006; 55:324–327. [PubMed: 16844522]

Piali L, Fichtel A, Terpe HJ, Imhof BA, Gisler RH. Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma. The Journal of experimental medicine. 1995; 181:811–816. [PubMed: 7530765]

Rogers HW, Weinstock MA, Harris AR, Hinckley MR, Feldman SR, Fleischer AB, et al. Incidence estimate of nonmelanoma skin cancer in the United States. Arch Dermatol. 2006; 146:283–287. [PubMed: 20231499]

Rohrl J, Yang D, Oppenheim JJ, Hehlgans T. Human beta-defensin 2 and 3 and their mouse orthologs induce chemotaxis through interaction with CCR2. J Immunol. 2010; 184:6688–6694. [PubMed: 20483750]

Tanese K, Grimm EA, Ekmekcioglu S. The role of melanoma tumor-derived nitric oxide in the tumor inflammatory microenvironment: Its impact on the chemokine expression profile, including suppression of CXCL10. International journal of cancer. 2011

Ulrich C, Bichel J, Euvrard S, Guidi B, Proby CM, van de Kerkhof PC, et al. Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. The British journal of dermatology. 2007; 157(Suppl 2):25–31. [PubMed: 18067628]

Warino L, Tusa M, Camacho F, Teuschler H, Fleischer AB Jr, Feldman SR. Frequency and cost of actinic keratosis treatment. Dermatol Surg. 2006; 32:1045–1049. [PubMed: 16918567]

Weishaupt C, Munoz KN, Buzney E, Kupper TS, Fuhlbrigge RC. T-cell distribution and adhesion receptor expression in metastatic melanoma. Clin Cancer Res. 2007; 13:2549–2556. [PubMed: 17473183]
Figure 1. E-selectin expression on tumor vasculature correlates quantitatively with infiltration by CLA$^+$ T cells

(a) Untreated human SCC lacked vascular expression of the skin T cell homing addressin E-selectin. Cryosections of tumor were co-stained for CD31 (a blood vessel marker, left panels) and E-selectin (right panels). SCC treated with the TLR7 agonist imiquimod showed up-regulation of E-selectin expression on tumor vessels (lower panels) Similar findings have been demonstrated in a total of 12 untreated tumors and six imiquimod treated tumors. Scale bar = 100 μM. (b) CLA$^+$ T cells are excluded from untreated human SCC but are present in imiquimod treated tumors. Shown are T cells isolated from untreated (upper panel) and imiquimod treated (lower panel) SCC tumors. (c) Exclusion of CLA$^+$ T cells from SCC was reversed by topical treatment with TLR7 agonist prior to excision. The absolute numbers of CLA$^+$ T cells per high power field (HPF) infiltrating untreated SCC (gray bars) and TLR7 agonist treated tumors (TLR7, black bars) are shown. (d) Vascular E-selectin expression correlated with the number of CLA-expressing T cells infiltrating SCC and histologic evidence of tumor regression. The mean and SEM for both the number of CLA-expressing T cells and the % E-selectin positive vessels are shown. These studies demonstrate a strong correlation of vascular E-selectin expression with the ability of tumors to recruit CLA$^+$ skin homing T cells. Tumors designated with an asterisk (*) had histologic evidence of tumor regression.
Figure 2. iNOS$^+$ cells infiltrating SCC tumors lack HLA-DR and express CD11b, a phenotype consistent with MDSC

(a,b) Co-staining of SCC cryosections demonstrated that iNOS$^+$ cells were evident in SCC tumors. (c,d) iNOS$^+$ cells lacked expression of the dendritic cell markers HLA-DR and CD11c, (e) the macrophage marker CD163, (f) the T cell marker CD3, and (g) the endothelial marker CD34. (h) iNOS$^+$ cells did express the myeloid marker CD11b. CD11b expression together with a lack of HLA-DR expression is a phenotype suggestive of MDSC. Similar findings were observed in a total of eight SCC tumors. Scale bar = 100 μM.
Figure 3. MDSC are a major source of nitric oxide production in SCC tumors
(a) SCC tumors were dispersed by treatment with collagenase and the population of CD11b+HLA-DR− cells were studied by flow cytometry. Most CD11b+HLA-DR− cells expressed CD33, approximately half expressed iNOS and over half produced TGFβ. Representative histograms are shown and the mean and SEM of multiple donors are shown on the right (n=5 for CD33 and iNOS, n=3 for TGFβ) (b) Arginase I was increased in CD11b+ cells isolated by magnetic bead separation from collagenase dispersed tumors as assayed by qRT-PCR. The mean and SEM of 3 donors are shown. (c) In collagenase dispersed tumors, a mean 6% of total tumor cells were CD11b+HLA-DR−CD33+ MDSC but these cells were rare in normal skin (Nml skin). (d) In many tumors, MDSC represented the majority of iNOS-expressing cells but non-MDSC cell types also expressed iNOS. (e) Analysis of SCC tumor supernatants using the Griess method demonstrated that NO was produced in SCC tumors. For each tumor, the mean and SEM of duplicate measurements of nitrate+nitrite are shown. (f,g) CD11b+ MDSC from SCC produce NO. CD11b+ MDSC were enriched by magnetic bead separation from collagenase treated tumors and cultured in vitro. Culture supernatants were analyzed for the presence of NO by the Griess method. The mean and SEM of measurements from three SCC are shown.
Figure 4. NO and MDSC from SCC inhibit human endothelial cell E-selectin expression

(a) Human skin dermal microvascular cells (DMEC) were stimulated with either TLR7 agonist activated APC (APC), mimicking physiologic stimulation, or the potent endothelial activator TNFβ in the presence or absence of the NO donor spermine NONOate (NO). Treated cells were immunostained for E-selectin and analyzed by flow cytometry. NO potently suppressed E-selectin upregulation in response to stimulated APC but only partially inhibited expression when endothelial cells were directly stimulated with TNFβ. (b) Percent inhibition of E-selectin expression by NO after stimulation with APC or TNFβ. The mean and SEM of three different endothelial donors are shown. Human umbilical vein endothelial cells (HUVEC) responded similarly in that NO completely abrogated E-selectin expression in response to stimulated APC (APC+NO) but only partially inhibited expression after stimulation with TNFβ. (c-e) MDSC from SCC suppress endothelial E-selectin expression in vitro. (c) Human HUVEC were stimulated with TNFβ in the presence or absence of collagenase dispersed cells from SCC tumors. A modest but reproducible inhibition in E-selectin expression was observed. Representative histograms and individual results from four SCC tumors are shown, along with the mean and SEM of these measurements. (d,e) CD11b+ MDSC from SCC tumors suppress endothelial E-selectin expression. CD11b+ and CD11b− cell populations were obtained by magnetic bead separation from collagenase dispersed SCC tumors. HUVEC were stimulated with TNFβ in the presence or absence of CD11b+ and CD11b− cells. (d) Representative histograms and (e) individual results from three SCC tumors are shown, along with the mean and SEM of these measurements. CD11b+ MDSC reproducibly inhibited expression of endothelial E-selectin.
Figure 5. MDSC from SCC express CCR2 and SCC produce the CCR2 ligand HBD3
(a) CD11b+HLA-DR− MDSC from collagenase dispersed SCC uniformly expressed CCR2 whereas CD3+ T cells lacked CCR2 expression. (b) Immunostaining of SCC cryosections confirmed that iNOS+ cells in SCC tumors co-express CCR2. (c) RT-PCR analysis of SCC tumors and normal human skin demonstrated selective production of the CCR2 ligand HBD3 in SCC. (d) Immunostaining of SCC cryosections confirmed production of HBD3 by SCC tumor cells. Scale bar = 100 μM.
Figure 6. Inhibition of iNOS activity restores vascular E-selectin expression in SCC tumors
(a) *In vitro* treatment of human SCC induced vascular E-selectin expression. SCC tumors
were cultured for 24 hours in medium alone, TNFβ or with the iNOS inhibitor L-NNA.
Tumors were then cryosectioned and stained for vascular E-selectin expression. SCC treated
with TNFβ or iNOS inhibitor showed induction of vascular E-selectin expression on a subset
of vessels. (b) iNOS inhibition potently induced vascular E-selectin expression. The mean
and SEM of the % E-selectin expressing vessels in 10 high-power fields are shown. *In vitro*
treatment of tumors with iNOS inhibitor induced vascular E-selectin at levels comparable to
or greater than that observed after treatment with TNFβ. Results from four SCC tumors are
shown; comparable results were observed in seven additional SCC. ***p<0.0005, **p<0.01,
*p<0.05. Scale bar = 500 μM.